^
    Back
    Association details:
    Biomarker:KDR amplification
    Cancer:Sarcoma
    Drug:Votrient (pazopanib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    JNCCN 360
    Title:

    Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib

    Excerpt:
    This report presents a patient with a sporadic, cutaneous angiosarcoma harboring high-level amplifications of members of the VEGFR family, specifically VEGFR2 (KDR; 8x) and VEGFR3 (FLT4; 16x). In response to pazopanib, an inhibitor of both VEGFR2 and VEGFR3, the patient experienced disease control for 6 month.
    DOI:
    10.6004/jnccn.2016.0058